Deubiquitylating Enzymes and DNA Damage Response Pathways
Identifieur interne : 001171 ( Main/Exploration ); précédent : 001170; suivant : 001172Deubiquitylating Enzymes and DNA Damage Response Pathways
Auteurs : Xavier Jacq [Royaume-Uni] ; Mark Kemp [Royaume-Uni] ; Niall M. B. Martin [Royaume-Uni] ; Stephen P. Jackson [Royaume-Uni]Source :
- Cell Biochemistry and Biophysics [ 1085-9195 ] ; 2013-09-01.
English descriptors
- KwdEn :
Abstract
Abstract: Covalent post-translational modification of proteins by ubiquitin and ubiquitin-like factors has emerged as a general mechanism to regulate myriad intra-cellular processes. The addition and removal of ubiquitin or ubiquitin-like proteins from factors has recently been demonstrated as a key mechanism to modulate DNA damage response (DDR) pathways. It is thus, timely to evaluate the potential for ubiquitin pathway enzymes as DDR drug targets for therapeutic intervention. The synthetic lethal approach provides exciting opportunities for the development of targeted therapies to treat cancer: most tumours have lost critical DDR pathways, and thus rely more heavily on the remaining pathways, while normal tissues are still equipped with all DDR pathways. Here, we review key deubiquitylating enzymes (DUBs) involved in DDR pathways, and describe how targeting DUBs may lead to selective therapies to treat cancer patients.
Url:
DOI: 10.1007/s12013-013-9635-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E25
- to stream Istex, to step Curation: 000E01
- to stream Istex, to step Checkpoint: 000322
- to stream Main, to step Merge: 001172
- to stream Main, to step Curation: 001171
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deubiquitylating Enzymes and DNA Damage Response Pathways</title><author><name sortKey="Jacq, Xavier" sort="Jacq, Xavier" uniqKey="Jacq X" first="Xavier" last="Jacq">Xavier Jacq</name></author><author><name sortKey="Kemp, Mark" sort="Kemp, Mark" uniqKey="Kemp M" first="Mark" last="Kemp">Mark Kemp</name></author><author><name sortKey="Martin, Niall M B" sort="Martin, Niall M B" uniqKey="Martin N" first="Niall M. B." last="Martin">Niall M. B. Martin</name></author><author><name sortKey="Jackson, Stephen P" sort="Jackson, Stephen P" uniqKey="Jackson S" first="Stephen P." last="Jackson">Stephen P. Jackson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:917E33B6AA86CFD886B630DA10508C8A05B7130E</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1007/s12013-013-9635-3</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-DPBVVX7G-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E25</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E25</idno><idno type="wicri:Area/Istex/Curation">000E01</idno><idno type="wicri:Area/Istex/Checkpoint">000322</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000322</idno><idno type="wicri:doubleKey">1085-9195:2013:Jacq X:deubiquitylating:enzymes:and</idno><idno type="wicri:Area/Main/Merge">001172</idno><idno type="wicri:Area/Main/Curation">001171</idno><idno type="wicri:Area/Main/Exploration">001171</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Deubiquitylating Enzymes and DNA Damage Response Pathways</title><author><name sortKey="Jacq, Xavier" sort="Jacq, Xavier" uniqKey="Jacq X" first="Xavier" last="Jacq">Xavier Jacq</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MISSION Therapeutics Ltd, Babraham Research Campus, CB22 3AT, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Kemp, Mark" sort="Kemp, Mark" uniqKey="Kemp M" first="Mark" last="Kemp">Mark Kemp</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MISSION Therapeutics Ltd, Babraham Research Campus, CB22 3AT, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Martin, Niall M B" sort="Martin, Niall M B" uniqKey="Martin N" first="Niall M. B." last="Martin">Niall M. B. Martin</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MISSION Therapeutics Ltd, Babraham Research Campus, CB22 3AT, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Stephen P" sort="Jackson, Stephen P" uniqKey="Jackson S" first="Stephen P." last="Jackson">Stephen P. Jackson</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MISSION Therapeutics Ltd, Babraham Research Campus, CB22 3AT, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Biochemistry, The Gurdon Institute, University of Cambridge, Cambridge</wicri:regionArea><orgName type="university">Université de Cambridge</orgName><placeName><settlement type="city">Cambridge</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Angleterre de l'Est</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Cell Biochemistry and Biophysics</title><title level="j" type="abbrev">Cell Biochem Biophys</title><idno type="ISSN">1085-9195</idno><idno type="eISSN">1559-0283</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2013-09-01">2013-09-01</date><biblScope unit="volume">67</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="25">25</biblScope><biblScope unit="page" to="43">43</biblScope></imprint><idno type="ISSN">1085-9195</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1085-9195</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Checkpoint control</term><term>DNA damage response</term><term>DNA repair</term><term>DUB</term><term>Deubiquitylating enzyme</term><term>Drug discovery</term><term>Synthetic lethality</term><term>Ubiquitin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Covalent post-translational modification of proteins by ubiquitin and ubiquitin-like factors has emerged as a general mechanism to regulate myriad intra-cellular processes. The addition and removal of ubiquitin or ubiquitin-like proteins from factors has recently been demonstrated as a key mechanism to modulate DNA damage response (DDR) pathways. It is thus, timely to evaluate the potential for ubiquitin pathway enzymes as DDR drug targets for therapeutic intervention. The synthetic lethal approach provides exciting opportunities for the development of targeted therapies to treat cancer: most tumours have lost critical DDR pathways, and thus rely more heavily on the remaining pathways, while normal tissues are still equipped with all DDR pathways. Here, we review key deubiquitylating enzymes (DUBs) involved in DDR pathways, and describe how targeting DUBs may lead to selective therapies to treat cancer patients.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Angleterre de l'Est</li></region><settlement><li>Cambridge</li></settlement><orgName><li>Université de Cambridge</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Jacq, Xavier" sort="Jacq, Xavier" uniqKey="Jacq X" first="Xavier" last="Jacq">Xavier Jacq</name></noRegion><name sortKey="Jackson, Stephen P" sort="Jackson, Stephen P" uniqKey="Jackson S" first="Stephen P." last="Jackson">Stephen P. Jackson</name><name sortKey="Jackson, Stephen P" sort="Jackson, Stephen P" uniqKey="Jackson S" first="Stephen P." last="Jackson">Stephen P. Jackson</name><name sortKey="Kemp, Mark" sort="Kemp, Mark" uniqKey="Kemp M" first="Mark" last="Kemp">Mark Kemp</name><name sortKey="Martin, Niall M B" sort="Martin, Niall M B" uniqKey="Martin N" first="Niall M. B." last="Martin">Niall M. B. Martin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001171 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001171 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:917E33B6AA86CFD886B630DA10508C8A05B7130E
|texte= Deubiquitylating Enzymes and DNA Damage Response Pathways
}}
| This area was generated with Dilib version V0.6.33. |  |